Major incorrect fact in the Annual Review of PHARMAC

Scoop

28 March 2019 - Today the Health Select Committee released their 2017/2018 Annual Review of PHARMAC. Sadly, and disappointingly, it is factually incorrect.

The review makes the following statement in relation to the petitions Metavivors (a group of people with advanced breast cancer) presented to the Health Select Committee (HSC) for the funding of the breast cancer drugs Ibrance and Kadcyla: “We heard that the medicines in question are currently funded for people who have not already received another hormonal treatment for metastatic breast cancer.”

The very reason we made submissions to the HSC is because these two drugs are not funded by PHARMAC and as of today this remains the case. Currently the funding application for Ibrance has received a positive recommendation by the Cancer Treatments Subcommittee (CaTSOP) in September 2018 for first line treatment for women who are yet to receive hormonal treatment for metastatic breast cancer and the Pharmaceutical and Therapeutics Advisory Committee (PTAC) that met in February this year are yet to release their recommendation.

Read Scoop article

Michael Wonder

Posted by:

Michael Wonder